Elliott et al. 20061717 O'Mahony C, Jichi F, Pavlou M, Monserrat L, Anastasakis A, Rapezzi C, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD). Eur Heart J. 2014;35(30):2010-20.
|
UK ;1988-2002 |
917 |
43 |
60.4 |
61 |
54 |
Elliott et al. 20001818 Debonnaire P, Katsanos S, Joyce E, VAN DEN Brink OV, Atsma DE, Schalij MJ, et al. QRS fragmentation and QTc duration relate to malignant ventricular tachyarrhythmias and sudden cardiac death in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2015;26(5):547-55.
|
UK; 1988-1998 |
368 |
37 |
64.9 |
43.2 |
22 |
Gimeno et al. 20091313 Syska P, Przybylski A, Chojnowska L, Lewandowski M, Sterlinski M, Maciag A, et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol. 2010;21(8):883-9.
|
UK; 1988 - 2004 |
1380 |
42 |
61.8 |
54 |
NI |
Kofflard et al. 20031919 Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. Heart. 2014;100(23):1851-8.
|
Netherlands; 1970-1999 |
225 |
41 |
57.7 |
96 |
20 |
Kofflard et al. 19932020 O'Hanlon R, Grasso A, Roughton M, Moon JC, Clark S, Wage R, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56(11):867-74.
|
Netherlands; 1970-1990 |
113 |
38 |
53.09 |
87.6 |
9 |
Maron B et al. 20072121 Almquist AK, Montgomery JV, Haas TS, Maron BJ. Cardioverter-defibrillator implantation in high-risk patients with hypertrophic cardiomyopathy. Heart Rhythm. 2005;2(8):814-9.
|
Multicentric; 1983-2005 |
383 |
41 |
62.9 |
44.4 |
51 |
Maron M et al. 20032222 Jayatilleke I, Doolan A, Ingles J, McGuire M, Booth V, Richmond DR, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol. 2004;93(9):1192-4.
|
USA and Italy; 1983- 2001 |
1101 |
45 |
59.4 |
75.6 |
71 |
Michaelides et al. 20092323 Maron BJ, Spirito P. Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol. 2008;19(10):1118-26.
|
Greece; 1999-2001 |
81 |
42 |
70.3 |
63.6 |
8 |
Monserrat et al. 20031212 Spirito P, Autore C, Rapezzi C, Bernabò P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1703-10.
|
UK; 1988-2000 |
531 |
39 |
60.8 |
70 |
32 |
Rubinshtein et al. 20102424 Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012;5(5):552-9.
|
USA; 2001-2007 |
424 |
55 |
59.1 |
43 |
8 |
Spirito et al. 20092525 Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51(14):1369-74.
|
USA and Italy; 1983-2005 |
1511 |
46 |
61.3 |
67.2 |
74 |
Spirito et al. 20001111 Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P, et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail. 2010;3(1):51-8.
|
USA and Italy; 1983-1997 |
480 |
47 |
60 |
78 |
23 |
Syska et al. 20102626 Shiozaki AA, Senra T, Arteaga E, Martinelli Filho M, Pita CG, Ávila LF, et al. Myocardial fibrosis detected by cardiac CT predicts ventricular fibrillation/ventricular tachycardia events in patients with hypertrophic cardiomyopathy. J Cardiovasc Comput Tomogr. 2013;7(3):173-81.
|
Poland; 1996-2006 |
78 |
36.4 |
47.4 |
55.2 |
13 |
Chan et al. 20141414 Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, et al. Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors. Am J Cardiol. 2014;113(9):1550-5.
|
USA and Italy: 2001-2010 |
1293 |
46 |
63 |
39.6 |
37 |
Spirito et al. 20142727 Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial fibrosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: a meta-analysis. Heart. 2015;101(17):1406-11.
|
Multicentric; 1990-2009 |
653 |
44.4 |
70.5 |
63.6 |
24 |
Magnusson et al. 20162828 Vriesendorp PA, Schinkel AF, Liebregts M, Theuns DA, van Cleemput J, Ten Cate FJ, et al. Validation of the 2014 European Society of Cardiology guidelines risk prediction model for the primary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2015;8(4):829-35.
|
Sweden; 1995-2002 |
237 |
52 |
69.2 |
64.8 |
77 |
Klopotowski et al. 20152929 Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology sudden death risk model for hypertrophic cardiomyopathy. Am J Cardiol. 2015;116(5):757-64.
|
Poland; 2008-2013 |
328 |
45 |
58.5 |
37 |
14 |
Mahony et al. 20143030 Christiaans I, van Engelen K, van Langen IM, Birnie E, Bonsel GJ, Elliott PM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace. 2010;12(3):313-21.
|
Multicentric |
3675 |
48 |
63.9 |
68.4 |
198 |
Debonmaire et al. 20153131 Oliveira DC, Assunção FB, Santos AA, Nacif MS. Cardiac magnetic resonance and computed tomography in hypertrophic cardiomyopathy: an update. Arq Bras Cardiol. 2016;107(2):163-72.
|
Netherlands and Belgium |
195 |
52 |
61 |
68.4 |
26 |
Ismail et al. 201432
|
UK; 2000-2011 |
711 |
55 |
70.4 |
42 |
22 |
O´Hanlon et al. 201033
|
UK; 2000-2006 |
217 |
53.2 |
70.5 |
37.2 |
12 |